Latest News about AZN
Recent news which mentions AZN
1 Stock Defying the Downturn to Buy, and 1 to Avoid
January 06, 2023
From Motley Fool
AstraZeneca's Current Valuation Not Reflective Of Its Strong Fundamentals, Analyst Says
January 05, 2023
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
From Benzinga
3 Top Healthcare Stocks Defying the Bear Market
January 03, 2023
From Motley Fool
Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study
January 03, 2023
From Benzinga
Why Shares of Compugen Rose on Thursday
December 29, 2022
From Motley Fool
Got $1,000? 5 Sensational Stocks to Buy to Start 2023 With a Bang
December 26, 2022
From Motley Fool
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
December 24, 2022
From Motley Fool
The Top Healthcare Stocks to Buy With $100
December 22, 2022
From Motley Fool
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
December 21, 2022
From Benzinga
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
December 20, 2022
From Benzinga
Could AstraZeneca's Asthma Drug Candidate Generate Billions?
December 20, 2022
From Motley Fool
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
December 19, 2022
From Benzinga
From Benzinga
AstraZeneca’s Forxiga gets EU approval recommendation for symptomatic chronic heart failure
December 19, 2022
Tickers
AZN
From MarketWatch
AstraZeneca’s Imfinzi plus Imjudo recommended for approval in the EU
December 19, 2022
Tickers
AZN
From MarketWatch
Guardant Health (GH) Stock Sinks on Disappointing Blood Test Results
December 16, 2022
From InvestorPlace
2 Best Biotech Stocks to Buy Right Now
December 16, 2022
From Motley Fool
From Benzinga
Netflix, Workday, Costco, Caterpillar and more: These stocks are Cowen’s favorites for 2023
December 10, 2022
From MarketWatch
2 Top Healthcare Stocks to Buy for the Long Haul
December 09, 2022
From Motley Fool
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
December 09, 2022
From Benzinga
AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
December 08, 2022
From Benzinga
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
December 07, 2022
From Benzinga
US Supports Delay On COVID Patent Waiver Extension Decision
December 06, 2022
From Benzinga
Is Amgen Stock a Buy for Income Investors?
December 02, 2022
From Motley Fool
2 Stocks That Could Surprise Investors in 2023
December 01, 2022
From Motley Fool
Why Shares of Compugen Rose 16.5% on Wednesday
November 30, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.